222 related articles for article (PubMed ID: 28004432)
21. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy.
Sallah S; Husain A; Sigounas V; Wan J; Turturro F; Sigounas G; Nguyen NP
Clin Cancer Res; 2004 Nov; 10(21):7238-43. PubMed ID: 15534097
[TBL] [Abstract][Full Text] [Related]
22. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
[TBL] [Abstract][Full Text] [Related]
23. Preoperative D-dimers as an independent prognostic marker in cervical carcinoma.
Luo YL; Chi PD; Zheng X; Zhang L; Wang XP; Chen H
Tumour Biol; 2015 Nov; 36(11):8903-11. PubMed ID: 26071675
[TBL] [Abstract][Full Text] [Related]
24. Carcinoma-associated antigens MK-1 and CEA in urological cancers.
Tomita Y; Arakawa F; Hirose Y; Liao S; Khare PD; Kuroki M; Yamamoto T; Ariyoshi A; Kuroki M
Anticancer Res; 2000; 20(2A):793-7. PubMed ID: 10810356
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma.
Sanders I; Holdenrieder S; Walgenbach-Brünagel G; von Ruecker A; Kristiansen G; Müller SC; Ellinger J
Int J Urol; 2012 Nov; 19(11):1017-25. PubMed ID: 22788411
[TBL] [Abstract][Full Text] [Related]
26. [Metastatic prostate cancer complicated with chronic disseminated intravascular coagulopathy causing acute renal failure, mimicking thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: pathomechanism, differential diagnosis and therapy related to a case].
Deme D; Ragán M; Kalmár K; Kovács L; Varga E; Varga T; Rakonczai E
Magy Onkol; 2010 Dec; 54(4):351-7. PubMed ID: 21163766
[TBL] [Abstract][Full Text] [Related]
27. Clinical and prognostic significance of coagulation assays in gastric cancer.
Tas F; Ciftci R; Kilic L; Serilmez M; Karabulut S; Duranyildiz D
J Gastrointest Cancer; 2013 Sep; 44(3):285-92. PubMed ID: 23536321
[TBL] [Abstract][Full Text] [Related]
28. Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
Gieseler F; Lühr I; Kunze T; Mundhenke C; Maass N; Erhart T; Denker M; Beckmann D; Tiemann M; Schulte C; Dohrmann P; Cavaillé F; Godeau F; Gespach C
Thromb Haemost; 2007 Jun; 97(6):1023-30. PubMed ID: 17549306
[TBL] [Abstract][Full Text] [Related]
29. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
31. The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading - a matched-pair analysis.
Berg KD; Thomsen FB; Nerstrøm C; Røder MA; Iversen P; Toft BG; Vainer B; Brasso K
BJU Int; 2016 Jun; 117(6):883-9. PubMed ID: 26823232
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of plasma D-dimer levels in lung carcinoma.
Komurcuoglu B; Ulusoy S; Gayaf M; Guler A; Ozden E
Tumori; 2011; 97(6):743-8. PubMed ID: 22322841
[TBL] [Abstract][Full Text] [Related]
33. Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer.
Wan YP; Xi M; He HC; Wan S; Hua W; Zen ZC; Liu YL; Zhou YL; Mo RJ; Zhuo YJ; Luo HW; Jiang FN; Zhong WD
Oncol Res Treat; 2017; 40(1-2):15-20. PubMed ID: 28118628
[TBL] [Abstract][Full Text] [Related]
34. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer.
Haubold K; Rink M; Spath B; Friedrich M; Chun FK; Marx G; Amirkhosravi A; Francis JL; Bokemeyer C; Eifrig B; Langer F
Thromb Haemost; 2009 Jun; 101(6):1147-55. PubMed ID: 19492160
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy.
Wang Y; Yin W; Wang Z; Huang J; Pan J; Zhu Y; Xu F; Shao X; Sha J; Cai Y; Liu Q; Dong B; Xue W; Huang Y
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):209-15. PubMed ID: 26951714
[TBL] [Abstract][Full Text] [Related]
36. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Tumour Biol; 2001; 22(5):282-5. PubMed ID: 11553857
[TBL] [Abstract][Full Text] [Related]
37. [Coagulation tests in septic surgical patients].
Oberhofer D; Kucisec-Tepes N; Skok J; Vucić N; Cala K
Acta Med Croatica; 2004; 58(5):389-94. PubMed ID: 15756805
[TBL] [Abstract][Full Text] [Related]
38. Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.
Wang Y; Xu F; Pan J; Zhu Y; Shao X; Sha J; Wang Z; Cai Y; Liu Q; Dong B; Xue W; Huang Y
BMC Cancer; 2016 May; 16():329. PubMed ID: 27222030
[TBL] [Abstract][Full Text] [Related]
39. Double Positive CD4
Bohner P; Chevalier MF; Cesson V; Rodrigues-Dias SC; Dartiguenave F; Burruni R; Tawadros T; Valerio M; Lucca I; Nardelli-Haefliger D; Jichlinski P; Derré L
Front Immunol; 2019; 10():622. PubMed ID: 30984190
[TBL] [Abstract][Full Text] [Related]
40. Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol.
Meye A; Bilkenroth U; Schmidt U; Füssel S; Robel K; Melchior AM; Blümke K; Pinkert D; Bartel F; Linne C; Taubert H; Wirth MP
Int J Oncol; 2002 Sep; 21(3):521-30. PubMed ID: 12168095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
